causing the restriction of tumour growth. It is not cytotoxic and would not be expected to cause reduction in tumour size in human studies. As the drugÕs actions were anticipated to be subtle, it was thought that trial design employing conventional radiological, clinical or serological measurements of tumour response or progression might fail to detect clinically important activity. An alternative might be trials assessing ÔresponseÕ in terms of maintenance of stable disease. However, it was not considered suitable initially to treat patients for longer than 28 days with this new class of drug. The relevance of disease stability over such a short period is questionable. Therefore, a novel approach to the conduct of phase I and II trials was undertaken in the early development of marimastat.
It was proposed that changes in the levels of the glycoprotein carcinoembryonic antigen (CEA) could be employed as a surrogate marker for the biological activity of marimastat in patients with colorectal cancer. CEA has been used in the clinical management of patients with colorectal cancer for more than three decades (Gold and Freedman, 1965) , and has found roles in the detection of recurrent disease (Minton et al, 1985; Quentmeier et al, 1990; Hida et al, 1996) and the monitoring of response to chemotherapy in patients with advanced cancer (Allen-Mersh et al, 1987; Ward et al, 1993) . Correlations have been observed between the rate of rise of CEA and reduced survival, and between falls in CEA and improved survival, in patients being treated for colorectal cancer (Sugarbaker et al, 1976; Allen-Mersh et al, 1987; Nakayama et al, 1997) . These correlations are not obscured by substantial interpatient variability in baseline CEA concentrations (Allen-Mersh et al, 1987) .
Expression of many of the MMPs has been reported in colorectal cancer (Levy et al, 1991; Gray et al, 1993; Zucker et al, 1993; Newell et al, 1994) ; increased expression of gelatinase B (MMP-9) has been implicated as an independent predictor of recurrence and outcome (Zeng et al, 1996) , and expression of matrilysin (MMP-7) has been correlated with disease progression (Ishikawa, 1996) . Moreover, MMP inhibitors have been shown to be effective in reducing tumour growth and spread in several xenograft models of human colorectal cancer (Wang et al, 1994; Watson et al 1995; An et al, 1997) .
On the basis of these observations, colorectal cancer was chosen as one of the target cancers to be assessed in the marimastat early trial programme, some of the results of which have now been published (Nemunaitis et al, 1998) . By examining the effect of marimastat upon the rate of rise of serum CEA, this study aimed to explore the relationship between marimastat dosing and detectable biological effects. In addition, it aimed to evaluate the tolerability of a range of doses and schedules of marimastat in patients with advanced colorectal cancer. The study was sponsored by British Biotech Pharmaceuticals, Oxford, UK, who supplied the drug.
PATIENTS AND METHODS

Patients
Patients with previously resected histologically proven colorectal cancer were selected for this study on the basis of a level of CEA above 5 ng ml Ð1 , and rising by 25% or more over a 4-week period, before study entry. An Eastern Cooperative Oncology Group (ECOG) performance status of 0Ð2 and a predicted survival of 3 months or more was required. Patients may have received prior chemotherapy, but were excluded if (i) surgery had been performed in the previous month; (ii) bilirubin and liver enzymes were greater than three times, and creatinine greater than twice, the upper limit of normal; (iii) albumin was less than 25 gl Ð1 ; or (iv) if there was evidence of weight loss greater than 10% in the previous 3 months.
Patients were recruited into the study from seven centres, five in the UK and two in Belgium. The protocol and protocol amendments were reviewed by the research ethics committee at each investigational centre and approved. All patients provided witnessed written informed consent to participate in the study, and the study was conducted in accordance with the European Guidelines on Good Clinical Practice.
Objectives
This study aimed to investigate the effect of marimastat on the rate of rise of CEA and to define the safety and tolerability of 4 weeks administration of the drug. Together with the assessment of the pharmacokinetic profiles of marimastat, these measures were to determine an effective dose range, with adequate tolerability for longer term studies.
Treatment
Gel capsules containing 5, 10, 25 or 50 mg of marimastat were provided by British Biotech Pharmaceuticals, Oxford, UK. Patients received their first dose of marimastat after satisfactory completion of screening procedures at Ð5 and Ð1 weeks. It was originally intended in this open pilot dose-escalation study that sequential groups of ten patients would receive doses of 25, 50 and 100 mg twice daily for a period of 28 days. The starting dose of 25 mg twice daily was decided on the basis of data from healthy volunteer studies , and escalation beyond each dose level was dependent on satisfactory safety data received from patients treated up to that time. Each group was to complete recruitment before the study progressed to the next dose. In the event, pharmacokinetic and safety data ruled out escalation beyond the 50 mg dose, and dose de-escalation occurred, with sequential groups of patients recruited at 10 mg twice daily, 10 mg once daily, 5 mg once daily and 20 mg once daily.
Continued administration of marimastat was allowed beyond 28 days in patients who were considered to be responding to therapy as defined by the response criteria below, or when in the opinion of the investigator the patient was benefiting from the drug. Dose reduction was possible when patients experienced marimastatrelated toxicity of less than grade 3.
End points
After screening, samples were taken for the measurement of CEA at days 0, 7, 14 and 28. CEA measurements were made at local laboratories with each patientÕs results being measured by the same laboratory. Inter-laboratory variability was not anticipated to confound results because rates of rise of CEA levels rather than absolute values were used for analysis of results. Criteria for response were defined as follows: a biological effect was defined as a rate of rise of CEA during the 28-day marimastat treatment period ²0%; a partial biological effect was defined as a rate of rise of CEA during marimastat treatment >0% and ²25%; non-responders were defined as those patients displaying a rate of rise of CEA during marimastat treatment of >25%, or who withdrew because of disease progression, or who died within 6 weeks of starting treatment. In the absence of evaluable screening or treatment data, patients were considered to be non-evaluable.
Because samples were not always taken at scheduled times, a computerized preanalysis algorithm was devised which selected the most appropriate antigen measurements for analysis in an unbiased manner (see below). In these analyses, 48 out of 55 (87%) evaluable patients had the required screening antigen measurements recorded within 6 weeks before entry, and 45 out of 55 (82%) had treatment antigen values recorded at the precise protocolized times.
After review of the results of changes in CEA levels, analysis was also made of the effect of marimastat on lactate dehydrogenase (LDH). This enzyme is a marker of cellular turnover and destruction and is biochemically unrelated to cancer antigen expression. LDH levels have been used to guide prognosis in patients with cancer, and have been shown to be associated with time to disease progression and predictive of survival in colorectal cancer (Schwartz, 1992; Fountzilas et al, 1996) .
Blood samples were taken for pharmacokinetic evaluation on days 0 (0 and 2 h), 14 and 28. Further samples were taken in patients receiving marimastat for more than 28 days. Clinical chemistry and haematology, urinalysis and vital signs were monitored throughout the stud y. All adverse events were recorded, whether thought related to marimastat or not.
Application of algorithm for tumour marker measurement
The computerized algorithm was derived from the study protocol and stipulated that patients were to have two screening (S1 and S2) and two treatment (T1 and T2) CEA values determined at the same laborator y. S1 was to be measured more than 2 weeks before S2, but less than 13 weeks before the start of the study. S2 must have been taken within 4 weeks of the start of treatment, and be greater than 5 ng ml Ð1 . The rate of rise of CEA averaged over 28 days must have been ³25%. T1 was required to be measured less than 7 days before, and less than 2 days after the start of treatment. T2 was to be measured between 22 and 34 days after the start of treatment, but no more than 2 days after the discontinuation of treatment. All patients who failed to meet one or more of these inclusion criteria were to be excluded from the primary analyses.
Statistical analysis
Categorical data were analysed using th e χ 2 test. Differences between patient groups at baseline were analysed using KruskalÐWallis and Wilcoxon tests. Continuous data were analysed by the Wilcoxon signed rank test and Wilcoxon rank sum test. Before results were analysed, a comparison of patients receiving once daily doses and patients receiving twice daily doses was planned.
RESULTS
Patient population
A total of 70 patients were recruited, of whom seven did not complete the 28-day treatment period; five of these seven were evaluable for toxicity and two failed to attend. Three of the five discontinued because of adverse events, one patient died and one experienced disease progression. Of 63 patients completing the first part of the study, 31 continued receiving marimastat for periods of up to 316 days.
Patient characteristics are listed in Table 1 including data by dose group. Colorectal adenocarcinoma was confirmed in 65 patients; the remaining five patients were recorded as having colorectal cancer of unconfirmed histological type. All but two patients had unde rgone surgery for their cance r, and most had received chemotherapy, predominantly for treatment of recurrent disease. At the time of entry into the study, 68 patients had radiological evidence of visceral metastatic disease, one had lymphatic metastases, and one had regional disease onl y. Patients were recruited in approximately equal numbers to each of the dose groups. No baseline characteristics were significantly di fferent between dose groups, or between patients treated by once daily or twice daily doses. 
Efficacy assessments
In total, 55 (79%) of the 70 patients were eligible for cancer antigen analysis under the rules of the algorithm. The 15 patients excluded from analysis comprised three who failed to complete the study (for reasons other than death or disease progression, this group being categorized as non-responders), 11 who had absent or invalid screening or treatment data, and one whose screening rate of rise was less than 25%. The results categorized by biological effect (²0% rise) and partial biological effect (²25%, >0% rise) are shown by dose group in Table 2 and Figure 1 . Only partial biological effects were observed at 5 and 10 mg once daily. Both biological and partial biological effects were observed in the other four dose groups, with the highest combined effects seen at 10 and 50 mg twice daily. The proportion of patients showing a biological or partial biological effect was higher with twice daily than once daily dosing (16 out of 25, 64% compared with 11 out of 30, 37%, P = 0.043, χ 2 test). An additional eight patients with screening data ineligible by algorithm but with eligible treatment data were included in an intention to treat analysis. Results were essentially unchanged; the proportion of patients showing a biological or partial biological effect was higher with the twice daily than once daily dosing (20 out of 30, 67% compared with 14 out of 33, 42%, P = 0.054, χ 2 test).
Median rates of rise of CEA at screening and during treatment are illustrated in Figure 2 . Small falls were apparent in those patients receiving 5 and 10 mg once daily. Changes were more substantial in the higher dose groups, and the difference in those patients receiving twice daily doses of marimastat was more evident (P < 0.0001) than in those patients receiving marimastat once daily (P = 0.25). The same relationship was observed when the median differences between screen and treatment rates of rise of CEA were charted (Figure 3) . The median screening rate of rise of CEA was higher in those patients receiving 25 mg twice daily (91%) than for other groups (35Ð61%) (Figure 2 ), and this may explain the relatively low proportion of patients in this group showing biological or partial biological effects (Figure 1) .
Trough plasma levels of marimastat are presented by dose in Table 3 . For a given dose, trough plasma levels were three-to fourfold higher than that observed in healthy volunteers . This increase is probably related to pharmacokinetic differences between young healthy males and older patients with advanced malignancy. Considerable intersubject variability was apparent within dose groups, although, with the exception of the group receiving 10 mg once daily, an approximately linear relationship with mean values was observed with increasing dose. Patients were divided into quartiles on the basis of trough plasma levels, and the median difference in treatment and screening percentage rate of rise of CEA for each group was calculated. Median differences for the low (²23.0 µg l Ð1 ), low/middle (>23.0 Figure 1 Percentage biological effect (BE) and partial biological effects (PBE) by dose group, in which BE is defined as a CEA value on day 28 no greater than that on day 0 and PBE is defined as a rise in CEA over the 28-day treatment period of less than 25% and ²63.5 µg l Ð1 ), high/middle (>63.5 and ²138.0 µg l Ð1 ), and high (>138.0 µg l Ð1 ) quartiles were 35%, 33%, 65% and 52% respectively. Differences between the groups did not reach statistical significance.
A retrospective analysis was performed on the effect of marimastat on LDH. At day 28, the median percentage changes from baseline for the 5 mg once daily, 10 mg once daily, 20 mg once daily, 10 mg twice daily, 25 mg twice daily and 50 mg twice daily groups were +12.4%, +9.0%, Ð4.4%, Ð0.7%, Ð7.8% and Ð12.4% respectively. The changes in LDH levels were not significantly different when comparing twice and once daily dosing (P = 0.06).
Safety assessments
Sixty-eight patients were assessable for toxicity. Adverse events occurring in at least three patients in one of the dose groups during the study period are presented in Table 4 . This table incorporates all reported events, whether thought to be related to marimastat or not. The most commonly reported events were those related to the musculoskeletal and gastrointestinal systems. Four serious events were reported as being possibly related to marimastat, including single cases of fatigue, general body pain, renal dysfunction and jaundice. There were no obvious adverse trends in laboratory values with marimastat treatment, although many out of range values were recorded both before and during treatment.
When considering adverse events reported to be definitely, probably or possibly related to marimastat, it was apparent that the principal toxicity of marimastat reported in this study was the occurrence of reversible musculoskeletal events. Symptoms included myalgia, arthralgia and tendinitis, predominantly of the upper limbs. The times of occurrence of musculoskeletal symptoms requiring dose reduction or withdrawal are described in Table  5 . Although musculoskeletal events occurred in a dose-and timedependent fashion, no clear relationship was observed between the occurrence of musculoskeletal adverse events and trough serum levels of marimastat. Four other patients who completed the 28-day study period suffered musculoskeletal symptoms of at least moderate severity and, possibly for this reason, were not entered into the continuation protocol.
DISCUSSION
This study has taken a novel approach to the clinical development of a cytostatic agent in attempting to show biological activity by the effect of marimastat on the rates of rise of cancer antigens. It has succeeded in this by showing changes in the rates of rise of CEA in colorectal cancer which were suggestive of a dosedependent biological effect. These results allow estimation of a dose range suitable for longer term controlled studies, which might hope to establish the clinical efficacy of marimastat.
Biological and partial biological effects were seen most commonly in the patients treated with higher doses of marimastat; a significant increase in response was observed between those patients receiving marimastat twice daily and those receiving marimastat once daily. The dose-dependent effect on rate of rise of CEA was also apparent when assessing the relative falls in rate of rise of CEA between the dose groups. Increased effects on the rate of rise of CEA were observed with higher trough plasma levels of marimastat, although this was not statistically significant.
Selection of a population of cancer patients with rapidly rising CEA levels during screening would tend to produce regression to the mean during the study period. This may contribute to the falls in the rate of rise of CEA occurring in patients treated at the two lowest doses (5 and 10 mg once daily). It seems reasonable to conclude, however, that the more pronounced reductions observed in the four higher dose groups were the result of treatment. A treatment effect on the rate of rise of CEA can be subject to a variety of interpretations, including the possibility of biochemical modulation of CEA synthesis or cancer antigen shedding unrelated to tumour progression. This seems unlikely in view of the lack of effect of marimastat on CEA shedding in in vitro studies with colorectal cancer cells (data not shown) and the apparent doserelated reduction in LDH, an important marker of tumour activity (Schwartz, 1992; Fountzilas et al, 1996) . Finally, as a non-randomized study, patients with different characteristics could have been unevenly distributed across the marimastat doses, favouring the higher dose groups. Demographic data do not support this suggestion, although unmeasured variables may exist with the potential to confound results. Marimastat was well-tolerated in this study, with musculoskeletal events emerging as the principal treatment-related toxicity. Symptoms were more severe and developed more rapidly at the highest dose (50 mg twice daily), although were reversible. Other adverse events were encountered commonly, but in most instances reflected the nature of the underlying disease process rather than a drug effect. The four serious adverse events thought possibly related to marimastat also were thought at least as likely to be related to the underlying disease.
On the basis of the safety and tolerability data, and the effects on cancer antigens, a dose range of 20 mg once daily to 25 mg twice daily seems appropriate for longer term, randomized and controlled studies. These studies should aim to define both the efficacy of the drug in terms of hard clinical end points such as patient survival or ÔresponseÕ in terms of disease-free survival, and the long-term tolerability of this novel agent.
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